Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: Results of an observational cohort study

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Van Der Maas, Aatke ^a   Van Den Bemt, Bart J F ^a   Wolbink, Gertjan ^a   Van Den Hoogen, Frank H J ^a   Van Riel, Piet L C M ^b   Den Broeder, Alfons A ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti infliximab antibodies; Infliximab; Low disease activity; Rheumatoid arthritis; Serum trough levels; Therapeutic drug monitoring

Indexed keywords

ANTI INFLIXIMAB ANTIBODY; DRUG ANTIBODY; INFLIXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; KAPPA STATISTICS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PATIENT SELECTION; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866508983     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-184     Document Type: Article

References (21)

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. N Engl J Med 2000 343 1594 1602 10.1056/NEJM200011303432202 11096166
2. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, et al. Arthritis Rheum 2004 50 3432 3443 10.1002/art.20568 15529377
3. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T, Arthritis Rheum 2006 54 3782 3789 10.1002/art.22214 17133559
4. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K, Ann Rheum Dis 2009 68 1739 1745 10.1136/ard.2008.092833 19019895
5. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T, Mod Rheumatol 2009 19 478 487 10.1007/s10165-009-0195-8 19626391
6. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Wolbink GJ, Voskuyl AE, Lems WF, de GE, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L, Ann Rheum Dis 2005 64 704 707 10.1136/ard.2004.030452 15485995
7. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de GE, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B, Arthritis Rheum 2006 54 711 715 10.1002/art.21671 16508927
8. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rodevand E, Kvien TK, Ann Rheum Dis 2011 70 12 2103 2110 10.1136/ard.2011.152363 21875874
9. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, de Rooij DJ, Brus HL, Van Oijen PC, et al. Ann Rheum Dis 2008 67 1229 1234 18174220
10. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T, Ann Rheum Dis 2010 69 1286 1291 10.1136/ard.2009.121491 20360136
11. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. den Broeder AA, van der Maas A, van den Bemt BJ, Rheumatology (Oxford) 2010 49 1801 1803 10.1093/rheumatology/keq060
12. van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, Van Riel PC, den Broeder AA, Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study 2012 Ann Rheum Dis annrheumdis-2011- 200945Published Online First: 13 April 2012
13. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, Del Ruiz AA, Martinez A, Aarden L, Martin-Mola E, et al. Rheumatology (Oxford) 2011 50 1445 1452 10.1093/rheumatology/ker124
14. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Ducourau E, Mulleman D, Paintaud G, Chu Miow LD, Lauferon F, Ternant D, Watier H, Goupille P, Arthritis Res Ther 2011 13 105 10.1186/ar3386 21708018
15. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Mulleman D, Meric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P, Arthritis Res Ther 2009 11 178 10.1186/ar2867 19939280
16. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ, JAMA 2011 305 1460 1468 10.1001/jama.2011.406 21486979
17. Measuring agreement in method comparison studies. Bland JM, Altman DG, Stat Methods Med Res 1999 8 135 160 10.1191/096228099673819272 10501650
18. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Rau R, Simianer S, van Riel PL, van De Putte LB, Kruger K, Schattenkirchner M, Allaart CF, Breedveld FC, Kempeni J, Beck K, et al. Scand J Rheumatol 2004 33 145 153 10.1080/03009740410005467 15228184
19. Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. van den Bemt BJ, den Broeder AA, Wolbink GJ, Hekster YA, van Riel PL, Benraad B, van den Hoogen FH, BMC Musculoskelet Disord 2011 12 12 10.1186/1471-2474-12-12 21232150
20. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW, Ann Rheum Dis 2007 66 Suppl 3 ii56 iii60 17934098
21. Improving the routine management of rheumatoid arthritis: the value of tight control. Mease PJ, J Rheumatol 2010 37 1570 1578 10.3899/jrheum.091064 20595287